Compare Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) vs Tango Therapeutics Inc. — how do they compare? Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.82 (market cap $158.90B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 42.4× Tango Therapeutics Inc.'s market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| SMFG | TNGX | |
|---|---|---|
Market Cap | $158.90B | $3.75B |
Volume | 1,175,519 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $27.56 | $32.90 |
52-Week Low | $15.69 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.70T | $2.77B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMFG trades at $25.21, up 0.72% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beating expectations with $0.50 EPS versus $0.44 expected, while Q4 2025 missed estimates. Revenue grew from $5.07T in 2025 to $6.14T in 2026 with net income margin improving to 27.8%. Analyst consensus shows 75% hold rating with institutional positions shifting recently.
SMFG presents a value opportunity with attractive valuation ratios (P/E 14.9, EV/EBITDA 5.16) and improving profitability, though technical weakness and mixed analyst sentiment suggest near-term caution. The stock faces risks from Japanese interest rate sensitivity and competitive pressures in global banking markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
